Nicotinamide Riboside
Status
No approved product. Marketed as a dietary ingredient. FDA has responded to GRAS notices for specific food uses of nicotinamide riboside (for example GRN 635) without questioning the notifier's conclusion; that concerns those food uses, not supplement approval or therapeutic efficacy.
What it is
An NAD precursor with several small human trials published.
What published research measured
A vitamin B3 derivative and NAD precursor. FDA has responded to GRAS notices for specific food uses (for example GRN 635) without questioning the notifier's conclusion; that is not approval of supplements. Randomized trials consistently show it raises blood NAD concentrations in a dose-dependent way and is well tolerated at studied intakes. Those same trials have generally failed to demonstrate downstream clinical benefit: studies in older adults have not shown convincing improvements in insulin sensitivity, mitochondrial function, muscle performance or cardiovascular measures despite the biomarker moving. This is the clearest example in the library of a compound where the mechanism does what it claims and the outcome has not followed.
Source
GRAS notifications for nicotinamide riboside; randomized trials showing raised NAD without downstream clinical benefit
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.